Clinical Trial Update: Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating sirolimus with tacrolimus for graft-versus-host disease prophylaxis after unrelated donor stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Graft-versus-host Disease
• Hodgkin Lymphoma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Myelogenous Leukemia, Graft Versus Host Disease | Phase 2 | Status: COMPLETED